

Application No. 09/529,654

Response to Office communication dated 01/19/2005

Amendment to the Claims:


This listing of claims will replace all previous versions, and listings, of claims in this application.

Listing of Claims:

Claims 1 - 43 (cancelled).

Claim 44 (currently amended)

A compound of formula I,



wherein

NRR^1 is attached at the 5- or 6-position of the furopyridine ring;

R is hydrogen, $\text{C}_1\text{-C}_4$ alkyl, or COR^2 ;

R^1 is $(\text{CH}_2)_n\text{Ar}_3\text{-CH}_2\text{CH=CHAr}$, or $\text{CH}_2\text{C}\equiv\text{CAr}$;

n is 0 to 3;

A is N;

Ar is a 5- or 6-membered aromatic or heteroaromatic ring which contains zero to four nitrogen atoms, zero to one oxygen atoms, and zero to one sulfur atoms; or:

Ar is an 8-, 9- or 10-membered fused aromatic or heteroaromatic ring system containing zero to four nitrogen atoms, zero to one oxygen atoms, and zero to one sulfur atoms; any of which may optionally be substituted with one to two substituents independently selected from: halogen; trifluoromethyl, or $\text{C}_1\text{-C}_4$ alkyl;

Application No. 09/529,654

Response to Office communication dated 01/19/2005

R^2 is hydrogen, C_1 - C_4 alkyl; C_1 - C_4 alkoxy; or a phenyl ring optionally substituted with one to three of the following substituents: halogen, C_1 - C_4 alkyl, C_2 - C_4 alkenyl, C_2 - C_4 alkynyl, OH, $-OC_1$ - C_4 alkyl, $-CO_2R^5$, $-CN$, $-NO_2$, $-NR^3R^4$, or $-CF_3$;

R^3 , R^4 and R^5 are independently hydrogen; C_1 - C_4 alkyl; or a phenyl ring optionally substituted with one to three of the following substituent : halogen, C_1 - C_4 alkyl, C_2 - C_4 alkenyl, C_2 - C_4 alkynyl, $-OH$, $-OC_1$ - C_4 alkyl, $-CN$, $-NO_2$, or $-CF_3$;
or an enantiomer thereof, or a pharmaceutically acceptable salt thereof, with the proviso that said compound is not 5'-N-benzylaminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'11)-furo[2,3-b]pyridine].

Claim 45 (cancelled)

Claim 46 (cancelled)

Claim 47 (cancelled)

Claim 48 (previously presented) A compound according to claim 44, wherein Ar is selected from

1-, or 2-naphthyl,
2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolyl,
1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolyl,
2-, 4-, 5-, 6-, or 7-benzoxazolyl, or
3-, 4-, 5-, 6-, or 7-benzisoxazolyl,

or an enantiomer thereof, or a pharmaceutically acceptable salt thereof

Application No. 09/529,654

Response to Office communication dated 01/19/2005

Claim 49 (cancelled)

Claim 50 (previously presented) A compound according to claim 44, wherein Ar is an heteroaromatic ring.

Claim 51 (cancelled)

Claim 52 (cancelled)

Claim 53 (cancelled)

Claim 54. (previously presented) A compound according to claim 44, said compound being:

R-(-)-5'-(3-pyridylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine], or

R-(-)-5'-(4-pyridylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'II)-furo[2,3-b]pyridine];

or an enantiomer thereof, or a pharmaceutically acceptable salt thereof.


Claim 55 (cancelled)

Application No. 09/529,654

Response to Office communication dated 01/19/2005

Claim 56 (cancelled)

Claim 57 (currently amended) A compound of formula I,



wherein

NRR¹ is attached at the 5- or 6-position of the furopyridine ring;R is hydrogen, C₁-C₄ alkyl, or COR²;R¹ is (CH₂)_nAr, CH₂CH=CHAr, or CH₂C≡CAr;

n is 0 to 3;

A is N;

Ar is a 5- or 6-membered aromatic or heteroaromatic ring which contains zero to four nitrogen atoms, zero to one oxygen atoms, and zero to one sulfur atoms which aromatic or heteroaromatic ring is optionally substituted with one to two substituents independently selected from: halogen, trifluoromethyl, or C₁-C₄alkyl;

R² is hydrogen, C₁-C₄alkyl; C₁-C₄alkoxy; or a phenyl ring optionally substituted with one to three of the following substituents: halogen, C₁-C₄alkyl, C₂-C₄alkenyl, C₂-C₄alkynyl, OH, -OC₁-C₄alkyl, -CO₂R⁵, -CN, -NO₂, -NR³R⁴, or -CF₃;

R³, R⁴ and R⁵ are independently hydrogen; C₁-C₄alkyl; or a phenyl ring optionally substituted with one to three of the following substituent: halogen, C₁-C₄alkyl, C₂-C₄alkenyl, C₂-C₄alkynyl, -OH, -OC₁-C₄alkyl, -CN, -NO₂, or -CF₃;

or an enantiomer thereof, or a pharmaceutically acceptable salt thereof.

Application No. 09/529,654

Response to Office communication dated 01/19/2005

Claim 58 (currently amended) A compound according to claim 57, wherein $[[R_1]]\underline{R}^1$ is $-\text{CH}_2\text{CH}=\text{CHAr}$.

Claim 59 (currently amended) A compound according to claim 57, wherein $[[R_1]]\underline{R}^1$ is $-\text{CH}_2\text{CH}\equiv\text{CHAr}$.

Claim 60 (currently amended) A compound according to claim 57, wherein $[[R_1]]\underline{R}^1$ is $-(\text{CH}_2)_n\text{Ar}$.

Claim 61 (previously presented) A compound according to claim 57, said compound being:

R-(-)-5'-(2-pyridylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-(3-pyridylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine][[, or]];

R-(-)-5'-(4-pyridylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-(2-furanylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-(3-furanylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-(2-thienylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

Application No. 09/529,654

Response to Office communication dated 01/19/2005

R-(-)-5'-(2-imidazolylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-(3-pyridyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-(3-thienylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-(imidazol-4-ylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-(thiazol-2-ylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-[trans-3-(4-pyridinyl)prop-2-enyl]aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-acetyl-N-(3-thienylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];

R-(-)-5'-N-methyl-N-(4-pyridylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine], or

R-(-)-5'-N-methyl-N-(3-pyridylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'H)-furo[2,3-b]pyridine];


or an enantiomer thereof, or a pharmaceutically-acceptable salt thereof.

Claim 62 (previously presented) A pharmaceutical composition comprising a compound according to claim 57, in admixture with an inert pharmaceutically-acceptable diluent or carrier.

Claim 63 (currently amended) A compound of formula I,

Application No. 09/529,654

Response to Office communication dated 01/19/2005



wherein

NRR^1 is attached at the 5- or 6-position of the furopyridine ring;

R is hydrogen, $\text{C}_1\text{-C}_4$ alkyl, or COR^2 ;

R^1 is $(\text{CH}_2)_n\text{Ar}$, $\text{CH}_2\text{CH}=\text{CHAr}$, or $\text{CH}_2\text{C}\equiv\text{CAr}$;

n is 0 to 3;

A is N;

Ar is an 8-, 9- or 10-membered fused aromatic or heteroaromatic ring system containing zero to four nitrogen atoms, zero to one oxygen atoms, and zero to one sulfur atoms which fused aromatic or heteroaromatic ring system is optionally substituted with one to two substituents independently selected from: halogen, trifluoromethyl, or $\text{C}_1\text{-C}_4$ alkyl;

R^2 is hydrogen, $\text{C}_1\text{-C}_4$ alkyl; $\text{C}_1\text{-C}_4$ alkoxy; or a phenyl ring optionally substituted with one to three of the following substituents: halogen, $\text{C}_1\text{-C}_4$ alkyl, $\text{C}_2\text{-C}_4$ alkenyl, $\text{C}_2\text{-C}_4$ alkynyl, OH, $-\text{OC}_1\text{-C}_4$ alkyl, $-\text{CO}_2\text{R}^5$, $-\text{CN}$, $-\text{NO}_2$, $-\text{NR}^3\text{R}^4$, or $-\text{CF}_3$;

R^3 , R^4 and R^5 are independently hydrogen; $\text{C}_1\text{-C}_4$ alkyl; or a phenyl ring optionally substituted with one to three of the following substituents: halogen, $\text{C}_1\text{-C}_4$ alkyl, $\text{C}_2\text{-C}_4$ alkenyl, $\text{C}_2\text{-C}_4$ alkynyl, OH, $-\text{OC}_1\text{-C}_4$ alkyl, $-\text{CN}$, $-\text{NO}_2$, or $-\text{CF}_3$;

or an enantiomer thereof, or a pharmaceutically acceptable salt thereof.

Claim 64 (currently amended)

A compound according to claim 63, wherein $[[\text{R}_1]]\text{R}^1$ is $-\text{CH}_2\text{CH}=\text{CHAr}$.

Application No. 09/529,654

Response to Office communication dated 01/19/2005

Claim 65 (currently amended) A compound according to claim 63, wherein $[[R_1]]R^1$ is $-CH_2CH=CHAr$.

Claim 66 (currently amended) A compound according to claim 63, wherein $[[R_1]]R^1$ is $-(CH_2)_nAr$.

Claim 67 (previously presented) A compound according to claim 63, said compound being:
R-(-)-5'-N-(quinolin-3-ylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'11)-furo[2,3-b]pyridine];
R-(-)-5'-N-(quinolin-4-ylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'11)-furo[2,3-b]pyridine], or
R-(-)-5'-N-(1,4-benzodioxan-6-ylmethyl)aminospiro[1-azabicyclo[2.2.2]octane-3,2'-(3'11)-furo[2,3-b]pyridine];
or an enantiomer thereof, or a pharmaceutically acceptable salt thereof.

Claim 68 (previously presented) A compound according to claim 63, wherein Ar is selected from 1-, or 2-naphthyl,
2-, 3-, 4-, 5-, 6-, 7-, or 8-quinolyl,
1-, 3-, 4-, 5-, 6-, 7-, or 8-isoquinolyl,
2-, 4-, 5-, 6-, or 7-benzoxazolyl, or
3-, 4-, 5-, 6-, or 7-benzisoxazolyl,
or an enantiomer thereof, or a pharmaceutically acceptable salt thereof.

Application No. 09/529,654

Response to Office communication dated 01/19/2005

Claim 69 (previously presented) A pharmaceutical composition comprising a compound according to claim 63, in admixture with an inert pharmaceutically-acceptable diluent or carrier.